{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T22:15:25Z","timestamp":1771539325116,"version":"3.50.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T00:00:00Z","timestamp":1588204800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T00:00:00Z","timestamp":1588204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100018592","name":"CELLTRION, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100018592","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s40259-020-00421-2","type":"journal-article","created":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T10:03:47Z","timestamp":1588241027000},"page":"513-528","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Post-Marketing Pooled Safety Analysis for CT-P13 Treatment of Patients with Immune-Mediated Inflammatory Diseases in Observational Cohort Studies"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9897-2163","authenticated-orcid":false,"given":"Sang Joon","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7589-0656","authenticated-orcid":false,"given":"KyungMin","family":"Baek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sujin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1727-0299","authenticated-orcid":false,"given":"Yoon Jee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2842-2347","authenticated-orcid":false,"given":"Jeong Eun","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seul Gi","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,30]]},"reference":[{"key":"421_CR1","unstructured":"US Food and Drug Administration. BLA approval: Inflectra. 2016. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2016\/125544Orig1s000ltr.pdf. Accessed 21 Aug 2019."},{"key":"421_CR2","unstructured":"European Medicines Agency. Inflectra. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/inflectra. Accessed 21 Aug 2019."},{"key":"421_CR3","unstructured":"European Medicines Agency. Remsima. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/remsima. Accessed 21 Aug 2019."},{"key":"421_CR4","unstructured":"Generics and Biosimilars Initiative. Biosimilar monoclonal antibody approved in Korea 2012. http:\/\/www.gabionline.net\/Biosimilars\/News\/Biosimilar-monoclonal-antibody-approved-in-Korea. Accessed 23 Sept 2019."},{"key":"421_CR5","unstructured":"European Medicines Agency. Inflectra Summary of Product Characteristics. 2019. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/inflectra-epar-product-information_en.pdf. Accessed 21 Aug 2019."},{"key":"421_CR6","unstructured":"US Food and Drug Administration. Inflectra Prescribing Information. 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/125544s009lbl.pdf. Accessed 21 Aug 2019."},{"key":"421_CR7","unstructured":"European Medicines Agency. Remsima Summary of Product Characteristics. 2019. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/remsima. Accessed 21 Aug 2019."},{"key":"421_CR8","unstructured":"European Medicines Agency. Remicade Summary of Product Characteristics. 2019. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/remicade-epar-product-information_en.pdf. Accessed 21 Aug 2019."},{"key":"421_CR9","unstructured":"US Food and Drug Administration. Remicade Prescribing Information. 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/103772s5385lbl.pdf. Accessed 21 Aug 2019."},{"issue":"10","key":"421_CR10","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1136\/annrheumdis-2012-203090","volume":"72","author":"DH Yoo","year":"2013","unstructured":"Yoo DH, Hrycaj P, Miranda P, Ramiterre E, Piotrowski M, Shevchuk S, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72(10):1613\u201320.","journal-title":"Ann Rheum Dis."},{"issue":"10","key":"421_CR11","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1136\/annrheumdis-2012-203091","volume":"72","author":"W Park","year":"2013","unstructured":"Park W, Hrycaj P, Jeka S, Kovalenko V, Lysenko G, Miranda P, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72(10):1605\u201312.","journal-title":"Ann Rheum Dis."},{"issue":"2","key":"421_CR12","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/ecco-jcc\/jjv220","volume":"10","author":"KB Gecse","year":"2016","unstructured":"Gecse KB, Lovasz BD, Farkas K, Banai J, Bene L, Gasztonyi B, et al. Efficacy and safety of the biosimilar infliximab CT-P13 treatment in inflammatory bowel diseases: a prospective, multicentre, nationwide cohort. J Crohns Colitis. 2016;10(2):133\u201340.","journal-title":"J Crohns Colitis."},{"issue":"2","key":"421_CR13","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/MIB.0000000000000995","volume":"23","author":"G Fiorino","year":"2017","unstructured":"Fiorino G, Manetti N, Armuzzi A, Orlando A, Variola A, Bonovas S, et al. The PROSIT-BIO cohort: a prospective observational study of patients with inflammatory bowel disease treated with infliximab biosimilar. Inflamm Bowel Dis. 2017;23(2):233\u201343.","journal-title":"Inflamm Bowel Dis."},{"issue":"4","key":"421_CR14","first-page":"392","volume":"32","author":"A Tursi","year":"2019","unstructured":"Tursi A, Mocci G, Faggiani R, Allegretta L, Valle ND, Forti G, et al. Infliximab biosimilar CT-P13 is effective and safe in treating inflammatory bowel diseases: a real-life multicenter, observational study in Italian primary inflammatory bowel disease centers. Ann Gastroenterol. 2019;32(4):392\u20139.","journal-title":"Ann Gastroenterol."},{"issue":"11","key":"421_CR15","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1097\/MIB.0000000000001237","volume":"23","author":"L Gonczi","year":"2017","unstructured":"Gonczi L, Gecse KB, Vegh Z, Kurti Z, Rutka M, Farkas K, et al. Long-term efficacy, safety, and immunogenicity of biosimilar infliximab after one year in a prospective nationwide cohort. Inflamm Bowel Dis. 2017;23(11):1908\u201315.","journal-title":"Inflamm Bowel Dis."},{"issue":"9","key":"421_CR16","doi-asserted-by":"crossref","first-page":"564","DOI":"10.17235\/reed.2018.5368\/2017","volume":"110","author":"MF Guerra Veloz","year":"2018","unstructured":"Guerra Veloz MF, Vazquez Moron JM, Belvis Jimenez M, Pallares Manrique H, Valdes Delgado T, Castro Laria L, et al. Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: results of a multicenter study after 12 months. Rev Esp Enferm Dig. 2018;110(9):564\u201370.","journal-title":"Rev Esp Enferm Dig."},{"issue":"Suppl. 1","key":"421_CR17","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1586\/17474124.2015.1091309","volume":"9","author":"SH Park","year":"2015","unstructured":"Park SH, Kim Y-H, Lee JH, Kwon HJ, Lee S-H, Park DI, et al. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea. Expert Rev Gastroenterol Hepatol. 2015;9(Suppl. 1):35\u201344.","journal-title":"Expert Rev Gastroenterol Hepatol."},{"issue":"2","key":"421_CR18","doi-asserted-by":"crossref","first-page":"99","DOI":"10.7326\/M18-1512","volume":"170","author":"A Meyer","year":"2019","unstructured":"Meyer A, Rudant J, Drouin J, Weill A, Carbonnel F, Coste J. Effectiveness and safety of reference infliximab and biosimilar in Crohn disease: a French equivalence study. Ann Intern Med. 2019;170(2):99\u2013107.","journal-title":"Ann Intern Med."},{"issue":"4","key":"421_CR19","doi-asserted-by":"crossref","first-page":"504","DOI":"10.5217\/ir.2019.00030","volume":"17","author":"T Nakagawa","year":"2019","unstructured":"Nakagawa T, Kobayashi T, Nishikawa K, Yamada F, Asai S, Sameshima Y, et al. Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice. Intest Res. 2019;17(4):504\u201315.","journal-title":"Intest Res."},{"issue":"5","key":"421_CR20","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1007\/s10620-017-4511-4","volume":"62","author":"F Arg\u00fcelles-Arias","year":"2017","unstructured":"Arg\u00fcelles-Arias F, Guerra Veloz MF, Perea Amarillo R, Vilches-Arenas A, Castro Laria L, Maldonado P\u00e9rez B, et al. Effectiveness and safety of CT-P13 (biosimilar infliximab) in patients with inflammatory bowel disease in real life at 6\u00a0months. Dig Dis Sci. 2017;62(5):1305\u201312.","journal-title":"Dig Dis Sci."},{"issue":"6","key":"421_CR21","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1080\/00365521.2018.1464203","volume":"53","author":"R Ratnakumaran","year":"2018","unstructured":"Ratnakumaran R, To N, Gracie DJ, Selinger CP, O\u2019Connor A, Clark T, et al. Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience. Scand J Gastroenterol. 2018;53(6):700\u20137.","journal-title":"Scand J Gastroenterol."},{"issue":"6","key":"421_CR22","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1080\/00365521.2018.1463391","volume":"53","author":"ML Hoivik","year":"2018","unstructured":"Hoivik ML, Buer LCT, Cvancarova M, Warren DJ, Bolstad N, Moum BA, et al. Switching from originator to biosimilar infliximab\u2014real world data of a prospective 18\u00a0months follow-up of a single-centre IBD population. Scand J Gastroenterol. 2018;53(6):692\u20139.","journal-title":"Scand J Gastroenterol."},{"key":"421_CR23","doi-asserted-by":"crossref","first-page":"175628481880124","DOI":"10.1177\/1756284818801244","volume":"11","author":"V Bergqvist","year":"2018","unstructured":"Bergqvist V, Kadivar M, Molin D, Angelison L, Hammarlund P, Olin M, et al. Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease. Ther Adv Gastroenterol. 2018;11:1756284818801244.","journal-title":"Ther Adv Gastroenterol."},{"issue":"8","key":"421_CR24","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1080\/14740338.2017.1323330","volume":"16","author":"A Balint","year":"2017","unstructured":"Balint A, Rutka M, Vegh Z, Kurti Z, Gecse KB, Banai J, et al. Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort. Expert Opin Drug Saf. 2017;16(8):885\u201390.","journal-title":"Expert Opin Drug Saf."},{"issue":"12","key":"421_CR25","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/j.cgh.2016.05.023","volume":"14","author":"S Ben-Horin","year":"2016","unstructured":"Ben-Horin S, Vande Casteele N, Schreiber S, Lakatos PL. Biosimilars in inflammatory bowel disease: facts and fears of extrapolation. Clin Gastroenterol Hepatol. 2016;14(12):1685\u201396.","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"2","key":"421_CR26","doi-asserted-by":"crossref","first-page":"267","DOI":"10.55563\/clinexprheumatol\/z0va6o","volume":"38","author":"HA Kim","year":"2020","unstructured":"Kim HA, Lee E, Lee SK, Park YB, Lee YN, Kang HJ, et al. Retention rate and long-term safety of biosimilar CT-P13 in patients with ankylosing spondylitis: data from the Korean College of Rheumatology Biologics registry. Clin Exp Rheumatol. 2020;38(2):267\u201374.","journal-title":"Clin Exp Rheumatol"},{"issue":"10","key":"421_CR27","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1080\/03007995.2018.1441144","volume":"34","author":"C Codreanu","year":"2018","unstructured":"Codreanu C, Sirova K, Jarosova K, Batalov A. Assessment of effectiveness and safety of biosimilar infliximab (CT-P13) in a real-life setting for treatment of patients with active rheumatoid arthritis or ankylosing spondylitis. Curr Med Res Opin. 2018;34(10):1763\u20139.","journal-title":"Curr Med Res Opin."},{"issue":"1","key":"421_CR28","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s12026-016-8843-5","volume":"65","author":"M Benucci","year":"2017","unstructured":"Benucci M, Gobbi FL, Bandinelli F, Damiani A, Infantino M, Grossi V, et al. Safety, efficacy and immunogenicity of switching from innovator to biosimilar infliximab in patients with spondyloarthritis: a 6-month real-life observational study. Immunol Res. 2017;65(1):419\u201322.","journal-title":"Immunol Res."},{"issue":"12","key":"421_CR29","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1517\/14712598.2015.1103733","volume":"15","author":"E Nikiphorou","year":"2015","unstructured":"Nikiphorou E, Kautiainen H, Hannonen P, Asikainen J, Kokko A, Rannio T, et al. Clinical effectiveness of CT-P13 (infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease Report of clinical experience based on prospective observational data. Expert Opin Biol Ther. 2015;15(12):1677\u201383.","journal-title":"Expert Opin Biol Ther."},{"key":"421_CR30","unstructured":"ClinicalTrials.gov. NCT02557295. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02557295. Accessed 20 Sept 2019."},{"key":"421_CR31","unstructured":"ClinicalTrials.gov. NCT02326155. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02326155. Accessed 20 Sept 2019."},{"key":"421_CR32","unstructured":"ClinicalTrials.gov. NCT02557308. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02557308. Accessed 20 Sept 2019."},{"key":"421_CR33","unstructured":"ClinicalTrials.gov. NCT02539368. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02539368. Accessed 20 Sept 2019."},{"key":"421_CR34","unstructured":"ClinicalTrials.gov. NCT02605642. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02605642. Accessed 20 Sept 2019."},{"key":"421_CR35","unstructured":"European Medicines Agency. Remsima: Public Assessment Report. 2013. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/remsima-epar-public-assessment-report_en.pdf. Accessed 21 Aug 2019."},{"key":"421_CR36","unstructured":"European Medicines Agency. Inflectra: Public Assessment Report. 2013. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/inflectra-epar-public-assessment-report_en.pdf. Accessed 21 Aug 2019."},{"issue":"9","key":"421_CR37","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/ajg.2012.218","volume":"107","author":"GR Lichtenstein","year":"2012","unstructured":"Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Price S, et al. Serious infection and mortality in patients with Crohn\u2019s disease: more than 5\u00a0years of follow-up in the TREAT\u2122 registry. Am J Gastroenterol. 2012;107(9):1409\u201322.","journal-title":"Am J Gastroenterol."},{"issue":"3","key":"421_CR38","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1136\/ard.2009.118935","volume":"69","author":"WG Dixon","year":"2010","unstructured":"Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis. 2010;69(3):522\u20138.","journal-title":"Ann Rheum Dis."},{"key":"421_CR39","unstructured":"World Health Organization. Global tuberculosis report. 2017. http:\/\/apps.who.int\/medicinedocs\/documents\/s23360en\/s23360en.pdf. Accessed 06 Feb 2020."},{"issue":"8","key":"421_CR40","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/acr.22290","volume":"66","author":"C Thorne","year":"2014","unstructured":"Thorne C, Bensen WG, Choquette D, Chow A, Khraishi M, Atkins CJ, et al. Effectiveness and safety of infliximab in rheumatoid arthritis: analysis from a Canadian multicenter prospective observational registry. Arthritis Care Res (Hoboken). 2014;66(8):1142\u201351.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"6","key":"421_CR41","first-page":"680","volume":"11","author":"G D\u2019Haens","year":"2017","unstructured":"D\u2019Haens G, Reinisch W, Colombel JF, Panes J, Ghosh S, Prantera C, et al. Five-year safety data from ENCORE, a European observational safety registry for adults with Crohn\u2019s disease treated with infliximab [Remicade\u00ae] or conventional therapy. J Crohns Colitis. 2017;11(6):680\u20139.","journal-title":"J Crohns Colitis."},{"issue":"9","key":"421_CR42","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1093\/ecco-jcc\/jjz048","volume":"13","author":"J Panes","year":"2019","unstructured":"Panes J, Lindsay JO, Teich N, Lindgren S, Colombel JF, Cornillie F, et al. Five-year safety data from OPUS, a European observational safety registry for adults with ulcerative colitis treated with originator infliximab [Remicade\u00ae] or conventional therapy. J Crohns Colitis. 2019;13(9):1148\u201357.","journal-title":"J Crohns Colitis."},{"issue":"3","key":"421_CR43","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1159\/000360618","volume":"89","author":"K Yoneno","year":"2014","unstructured":"Yoneno K, Hisamatsu T, Matsuoka K, Okamoto S, Takayama T, Ichikawa R, et al. Risk and management of intra-abdominal abscess in Crohn\u2019s disease treated with infliximab. Digestion. 2014;89(3):201\u20138.","journal-title":"Digestion."},{"issue":"4","key":"421_CR44","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/gut.2008.155812","volume":"58","author":"F Schnitzler","year":"2009","unstructured":"Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, Van Assche G, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn\u2019s disease: results from a single-centre cohort. Gut. 2009;58(4):492\u2013500.","journal-title":"Gut."},{"issue":"3","key":"421_CR45","doi-asserted-by":"crossref","first-page":"R121","DOI":"10.1186\/ar3058","volume":"12","author":"I Delabaye","year":"2010","unstructured":"Delabaye I, De Keyser F. 74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis. Arthritis Res Ther. 2010;12(3):R121.","journal-title":"Arthritis Res Ther."},{"issue":"9317","key":"421_CR46","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"SB Hanauer","year":"2002","unstructured":"Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541\u20139.","journal-title":"Lancet."},{"issue":"23","key":"421_CR47","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","volume":"353","author":"P Rutgeerts","year":"2005","unstructured":"Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462\u201376.","journal-title":"N Engl J Med."},{"issue":"2","key":"421_CR48","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/art.20852","volume":"52","author":"D van der Heijde","year":"2005","unstructured":"van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 2005;52(2):582\u201391.","journal-title":"Arthritis Rheum."},{"issue":"9194","key":"421_CR49","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","volume":"354","author":"R Maini","year":"1999","unstructured":"Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999;354(9194):1932\u20139.","journal-title":"Lancet."},{"issue":"4","key":"421_CR50","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/art.21734","volume":"54","author":"R Westhovens","year":"2006","unstructured":"Westhovens R, Yocum D, Han J, Berman A, Strusberg I, Geusens P, et al. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum. 2006;54(4):1075\u201386.","journal-title":"Arthritis Rheum."},{"issue":"8","key":"421_CR51","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1136\/ard.2007.080002","volume":"67","author":"M Schiff","year":"2008","unstructured":"Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis. 2008;67(8):1096\u2013103.","journal-title":"Ann Rheum Dis."},{"issue":"11","key":"421_CR52","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1002\/art.20568","volume":"50","author":"EW St Clair","year":"2004","unstructured":"St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 2004;50(11):3432\u201343.","journal-title":"Arthritis Rheum."},{"issue":"3","key":"421_CR53","doi-asserted-by":"crossref","first-page":"e012567","DOI":"10.1136\/bmjopen-2016-012567","volume":"7","author":"Z Zhang","year":"2017","unstructured":"Zhang Z, Fan W, Yang G, Xu Z, Wang J, Cheng Q, et al. Risk of tuberculosis in patients treated with TNF-alpha antagonists: a systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2017;7(3):e012567.","journal-title":"BMJ Open."},{"issue":"3","key":"421_CR54","doi-asserted-by":"crossref","first-page":"R77","DOI":"10.1186\/ar2997","volume":"12","author":"B Vander Cruyssen","year":"2010","unstructured":"Vander Cruyssen B, Durez P, Westhovens R, De Keyser F. Seven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease: attrition rate and evolution of disease activity. Arthritis Res Ther. 2010;12(3):R77.","journal-title":"Arthritis Res Ther."},{"issue":"1","key":"421_CR55","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/art.23167","volume":"58","author":"M Breban","year":"2008","unstructured":"Breban M, Ravaud P, Claudepierre P, Baron G, Henry YD, Hudry C, et al. Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. Arthritis Rheum. 2008;58(1):88\u201397.","journal-title":"Arthritis Rheum."},{"issue":"11","key":"421_CR56","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1007\/s00296-009-1157-3","volume":"30","author":"AR Giardina","year":"2010","unstructured":"Giardina AR, Ferrante A, Ciccia F, Impastato R, Miceli MC, Principato A, et al. A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis. Rheumatol Int. 2010;30(11):1437\u201340.","journal-title":"Rheumatol Int."},{"issue":"9313","key":"421_CR57","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","volume":"359","author":"J Braun","year":"2002","unstructured":"Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet. 2002;359(9313):1187\u201393.","journal-title":"Lancet."},{"issue":"3","key":"421_CR58","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/art.511","volume":"46","author":"F Van Den Bosch","year":"2002","unstructured":"Van Den Bosch F, Kruithof E, Baeten D, Herssens A, de Keyser F, Mielants H, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum. 2002;46(3):755\u201365.","journal-title":"Arthritis Rheum."},{"issue":"2","key":"421_CR59","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jaci.2005.12.1303","volume":"117","author":"HA Sampson","year":"2006","unstructured":"Sampson HA, Mu\u00f1oz-Furlong A, Campbell RL, Adkinson NF Jr, Bock SA, Branum A, et al. Second symposium on the definition and management of anaphylaxis: Summary report; Second National Institute of Allergy and Infectious Disease\/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol. 2006;117(2):391\u20137.","journal-title":"J Allergy Clin Immunol."}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-020-00421-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-020-00421-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-020-00421-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T11:09:21Z","timestamp":1744715361000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-020-00421-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,30]]},"references-count":59,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["421"],"URL":"https:\/\/doi.org\/10.1007\/s40259-020-00421-2","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,30]]},"assertion":[{"value":"30 April 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"CELLTRION, Inc., Incheon, Republic of Korea, and Pfizer Inc., New York, NY, USA, provided financial support for the observational studies. This analysis was funded by CELLTRION, Inc. (Incheon, Republic of Korea).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"SJL, KMB, SL, YJL, JEP, and SGL are employees of CELLTRION, Inc. (Incheon, Republic of Korea). SJL and KMB are shareholders in CELLTRION, Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in compliance with the ethical principles originating in or derived from the Declaration of Helsinki and with all International Council for Harmonisation good clinical practice guidelines. In addition, all local regulatory requirements were followed. The final protocol, any amendments and informed consent documentation were reviewed and approved by the institutional review boards and\/or independent ethics committees at each of the investigational centres participating in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Informed consent was obtained from all individual participants included in the studies.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}